Back to search results

THC and CBD: A Study on Harm Reduction

This study is looking into how cannabidiol (CBD), a non-intoxicating part of cannabis, might change the effects of tetrahydrocannabinol (THC), the part that causes a 'high.' Researchers want to see if CBD can help reduce any unwanted effects of THC and also if it affects pain relief. They will test different doses of vaporized CBD (20 mg, 40 mg, 80 mg) along with vaporized THC (20 mg) or a placebo (inactive substance). You might be able to join if you are between 21 and 55 years old, use cannabis 1-7 days a week, and are not currently seeking treatment for cannabis use. The study will measure how participants feel about the drug's effects, their pain levels using a cold pressor test, and their performance on certain tasks. The current status of this study is unclear.

Study design
This interventional study plans to enroll 30 participants. It will compare the effects of vaporized placebo, THC, and different doses of CBD.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcomes are measured at 3 hours after intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06859710

THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy

Recruiting
PHASE1Ages 21–55InterventionalBasic science
University of California, Los Angeles
~30 participants
Updated 2025-12-17 on ClinicalTrials.gov
What's tested:PlaceboTHCCBD 20 mgCBD 40 mgCBD 80 mg

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Subject-rated drug effects of abuse liability
Measured over 3 hours
+3 more outcomes measured

Conditions

Abuse, Drug
Pain

Explore related trials

Cannabis misuse

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Ziva Cooper, PhD · PRINCIPAL_INVESTIGATOR · University of California, Los Angeles

Who to contact

Ziva Cooper, PhD
[email protected]
310-206-9942
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or non-pregnant and non-lactating females aged 21-55 years
Report cannabis use 1-7 days per week over the month prior to screening
Not currently seeking treatment for their cannabis use
History of inhaled cannabis use
Have a Body Mass Index from 18.5 - 34 kg/m2
Able to perform all study procedures
Must be using a contraceptive (hormonal or barrier methods)

Exclusion

Meeting DSM-V criteria for severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine, mild or moderate CUD
Evidence of severe psychiatric illness (e.g. mood or anxiety disorder with functional impairment or suicide risk, schizophrenia) judged by the study physician (and PI) to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide informed consent.
Report using other illicit drugs in the prior 4 weeks
Current pain
Pregnancy
Currently enrolled in another research protocol
Not using a contraceptive method (hormonal or barrier methods)
Insensitivity to the cold water stimulus of the Cold Pressor Test
Any disorders that might make cannabis administration hazardous as determined by evaluation physician after review of all medical assessments along with medical history.
Not able to speak and read English

What this trial measures

  • Subject-rated drug effects of abuse liability3 hours

    Subject ratings of "Good Drug Effect" as measured using a visual analog scale (1-100 mm)

  • Analgesia as measured using the Cold Pressor Test3 hours

    Pain threshold assessed using the Cold Pressor Test (percent baseline)

  • Behavioral task performance as assessed by the DRUID App Score3 hours

    Trough composite scores on the DRUID App

  • Pharmacokinetics of THC3 hours

    Peak plasma levels of THC (ng/ml)